28
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CONSENSO LATINOAMERICANO DE HIPERTENSIÓN EN PACIENTES CON DIABETES TIPO 2 Y SÍNDROME METABÓLICO Translated title: LATIN AMERICAN CONSENSUS ON HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES AND METABOLIC SYNDROME Translated title: CONSENSO LATINOAMERICANO DE HIPERTENSÃO EM PACIENTES COM DIABETES TIPO 2 E SÍNDROME METABÓLICO

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          El presente documento ha sido preparado por un grupo de expertos, miembros de las sociedades de cardiología, endocrinología, medicina interna, nefrología y diabetes de los países de América Latina, para que sirva de guía a los médicos que cuidan a pacientes con diabetes, hipertensión y enfermedades concomitantes o complicaciones de ambas condiciones. Aunque el concepto de síndrome metabólico actualmente es discutido, la alta prevalencia en América Latina del conjunto de alteraciones metabólicas que lo conforman sugiere que el síndrome metabólico es una entidad nosografías útil en el contexto de la medicina latinoamericana. Por lo tanto, en el presente documento se presta especial atención a este síndrome con el fin de alertar a los médicos de una particular población de alto riesgo, en la que por lo general se subestimada y no se trata en forma optima los factores de riego que constituyen el síndrome metabólico. Las presentes recomendaciones son el resultado de las presentaciones y los debates en los paneles de discusión durante una reunión de 2 días celebrada en Bucaramanga en octubre de 2012. Todos los participantes han aprobado las conclusiones finales. Los autores reconocen que la publicación y difusión de las guías no serán suficientes para alcanzar los cambios recomendados, tanto en las estrategias diagnósticas como terapéuticas, por lo que se ha programado intervenciones que permitan identificar las barreras del conocimiento, de las actitudes y de comportamiento, lo que permitirá tanto a los médicos como a los pacientes una adecuada adherencia a las recomendaciones de las guías.

          Translated abstract

          The present document has been prepared by a group of experts, members of cardiology, endocrinology, internal medicine, nephrology and diabetes societies of Latin American Countries, to serve as a guide to physicians taking care of patients with diabetes, hypertension and comorbidities or complications of both conditions. Although the concept of metabolic syndrome is currently disputed, the higher prevalence in Latin America of that cluster of metabolic alterations has suggested that metabolic syndrome is useful nosography entity in the context of Latin American medicine. Therefore, in the present document, particular attention is paid to this syndrome in order to alert physicians on a particular high- risk population, usually underestimated and undertreated. These recommendations results from presentation and debates by discussion panels during a 2-day conference held in Bucaramanga, in October 2012, and all the participants have approved the final conclusions. The authors acknowledge that the publication and diffusion of guidelines do not suffice to achieve the recommended changes in diagnostic or therapeutic strategies, and plan suitable interventions overcoming both physicians and patients from effectively adhering to guideline recommendations.

          Translated abstract

          O presente documento tem sido preparado por um grupo de expertos, membros das sociedades de cardiologia, endocrinologia, medicina interna, nefrologiae diabetes dospaíses da América Latina, para que sirva de guia aos médicos que tomam conta de pacientes com diabetes, hipertensãoe enfermidades concomitantes ou complicaçõesdas duas condições. Porémoconceito de síndrome metabólico atualmente é discutido, a alta prevalênciana América Latina do conjunto de alterações metabólicas que o conformam,sugereque o síndrome metabólico é uma entidade nosográfica útil no contexto da medicina latino americana. Pelo tanto, no presente documento se presta especial atenção a este síndrome comofim de alertar aos médicos de una particular população de alto risco,a qual pelo geralé subestimada e não se trata em forma ótimaosfatores de risco que constituemo síndrome metabólico. As presentes recomendações sãoo resultado das apresentaçõeseos debates nos painéis de discussão durante una reunião de 2 dias celebrada em Bucaramanga em outubro de 2012. Todosos participantes têm aprovado as conclusões finais. Os autores reconhecem que a publicaçãoe difusão dos guias no serão suficientes para alcançar os câmbios recomendados tanto nas estratégiasdiagnósticas quanto terapêuticas, pelo que se têm programadointervenções que permitam identificar as barreiras do conhecimento, das atitudes e de comportamento, o que permitirá tanto aos médicos quanto aos pacientes una adequada aderênciaàs recomendações dos guias.

          Related collections

          Most cited references258

          • Record: found
          • Abstract: found
          • Article: not found

          2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.

          Hypertension is estimated to cause 4.5% of current global disease burden and is as prevalent in many developing countries, as in the developed world. Blood pressure-induced cardiovascular risk rises continuously across the whole blood pressure range. Countries vary widely in capacity for management of hypertension, but worldwide the majority of diagnosed hypertensives are inadequately controlled. This statement addresses the ascertainment of overall cardiovascular risk to establish thresholds for initiation and goals of treatment, appropriate treatment strategies for non-drug and drug therapies, and cost-effectiveness of treatment. Since publication of the WHO/ISH Guidelines for the Management of Hypertension in 1999, more evidence has become available to support a systolic blood pressure threshold of 140 mmHg for even 'low-risk' patients. In high-risk patients there is evidence for lower thresholds. Lifestyle modification is recommended for all individuals. There is evidence that specific agents have benefits for patients with particular compelling indications, and that monotherapy is inadequate for the majority of patients. For patients without a compelling indication for a particular drug class, on the basis of comparative trial data, availability, and cost, a low dose of diuretic should be considered for initiation of therapy. In most places a thiazide diuretic is the cheapest option and thus most cost effective, but for compelling indications where other classes provide additional benefits, even if more expensive, they may be more cost effective. In high-risk patients who attain large benefits from treatment, expensive drugs may be cost effective, but in low-risk patients treatment may not be cost-effective unless the drugs are cheap.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Why don't physicians follow clinical practice guidelines? A framework for improvement.

            Despite wide promulgation, clinical practice guidelines have had limited effect on changing physician behavior. Little is known about the process and factors involved in changing physician practices in response to guidelines. To review barriers to physician adherence to clinical practice guidelines. We searched the MEDLINE, Educational Resources Information Center (ERIC), and HealthSTAR databases (January 1966 to January 1998); bibliographies; textbooks on health behavior or public health; and references supplied by experts to find English-language article titles that describe barriers to guideline adherence. Of 5658 articles initially identified, we selected 76 published studies describing at least 1 barrier to adherence to clinical practice guidelines, practice parameters, clinical policies, or national consensus statements. One investigator screened titles to identify candidate articles, then 2 investigators independently reviewed the texts to exclude articles that did not match the criteria. Differences were resolved by consensus with a third investigator. Two investigators organized barriers to adherence into a framework according to their effect on physician knowledge, attitudes, or behavior. This organization was validated by 3 additional investigators. The 76 articles included 120 different surveys investigating 293 potential barriers to physician guideline adherence, including awareness (n = 46), familiarity(n = 31), agreement (n = 33), self-efficacy (n = 19), outcome expectancy (n = 8), ability to overcome the inertia of previous practice (n = 14), and absence of external barriers to perform recommendations (n = 34). The majority of surveys (70 [58%] of 120) examined only 1 type of barrier. Studies on improving physician guideline adherence may not be generalizable, since barriers in one setting may not be present in another. Our review offers a differential diagnosis for why physicians do not follow practice guidelines, as well as a rational approach toward improving guideline adherence and a framework for future research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effects of intensive blood-pressure control in type 2 diabetes mellitus.

              There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigated whether therapy targeting normal systolic pressure (i.e., <120 mm Hg) reduces major cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events. A total of 4733 participants with type 2 diabetes were randomly assigned to intensive therapy, targeting a systolic pressure of less than 120 mm Hg, or standard therapy, targeting a systolic pressure of less than 140 mm Hg. The primary composite outcome was nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years. After 1 year, the mean systolic blood pressure was 119.3 mm Hg in the intensive-therapy group and 133.5 mm Hg in the standard-therapy group. The annual rate of the primary outcome was 1.87% in the intensive-therapy group and 2.09% in the standard-therapy group (hazard ratio with intensive therapy, 0.88; 95% confidence interval [CI], 0.73 to 1.06; P=0.20). The annual rates of death from any cause were 1.28% and 1.19% in the two groups, respectively (hazard ratio, 1.07; 95% CI, 0.85 to 1.35; P=0.55). The annual rates of stroke, a prespecified secondary outcome, were 0.32% and 0.53% in the two groups, respectively (hazard ratio, 0.59; 95% CI, 0.39 to 0.89; P=0.01). Serious adverse events attributed to antihypertensive treatment occurred in 77 of the 2362 participants in the intensive-therapy group (3.3%) and 30 of the 2371 participants in the standard-therapy group (1.3%) (P<0.001). In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events. (ClinicalTrials.gov number, NCT00000620.) 2010 Massachusetts Medical Society
                Bookmark

                Author and article information

                Journal
                med
                Revista Med
                rev.fac.med
                Universidad Militar Nueva Granada. Facultad de Medicina (Bogotá, Distrito Capital, Colombia )
                0121-5256
                1909-7700
                June 2013
                : 21
                : 1
                : 113-135
                Affiliations
                [15] Bogotá orgnameSociedad Colombiana de Cardiología Colombia
                [13] Porto Alegre orgnameUniversidad de Rio Grande do Sul Brasil
                [14] Medellín orgnameCentro Médico Colombia
                [20] Milán orgnameInstituto Auxológico Italiano Italia
                [02] Buenos Aires orgnameFundación Favaloro orgdiv1Hospital Universitario orgdiv2Unidad de Metabolismo e Hipertensión Arterial Argentina
                [10] Bogotá orgnameAsociación Latinoamericana de Diabetes Colombia
                [01] Bucaramanga orgnameUniversidad de Santander UDES orgdiv1Fundación Oftalmológica de Santander FOSCAL Colombia
                [06] Guadalajara orgnameUniversidad de Guadalajara México
                [07] Bogotá orgnameUniversidad de la Sabana orgdiv1Asociación Colombiana de Endocrinología Colombia
                [11] Guayaquil orgnameHospital Luis Vernaza Ecuador
                [05] Lima orgnameClínica de Golf Perú
                [17] Ribeirao Preto orgnameUniversidad de Sao Paulo Brasil
                [16] Guayaquil orgnameSociedad Ecuatoriana de Aterosclerosis Ecuador
                [12] Córdova orgnameUniversidad de Córdova Argentina
                [03] Montevideo orgnameClínica Platinum Uruguay
                [18] Corozal orgnameFederación Diabetológica Colombiana Colombia
                [08] Temuco orgnameUniversidad de la Frontera Chile
                [09] Buenos aires orgnameInstituto Cardiológico de Buenos Aires Argentina
                [19] Melbourne orgnameUniversity of Melbourne Australia
                [04] Santiago orgnameColegio Panamericano del Endotelio Chile
                Article
                S0121-52562013000100012 S0121-5256(13)02100112
                355e81d6-fa95-43cd-ba9e-a2c8059e02e6

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 28 June 2013
                : 25 May 2013
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 144, Pages: 23
                Product

                SciELO Colombia

                Categories
                Artículos de revisión

                metabolic syndrome,Hipertensão arterial,diabetes,Hipertensión arterial,síndrome metabólico,Consenso Latinoamericano,Arterial hypertension,Latin American consensus,Consenso Latino Americano

                Comments

                Comment on this article